United Health Products Reports $315,842 Net Loss in Q1 2026, Focuses on Regulatory Approval for CelluSTAT

United Health Products, Inc. (UHP) reported its financial results for the first quarter of 2026, revealing a net loss of $315,842, a significant reduction from the $1,531,659 loss recorded in the same period of 2025. The company did not generate any revenue during the quarter, consistent with the previous year, as it continues to focus its resources on obtaining regulatory approval for its hemostatic gauze product, CelluSTAT. Total operating expenses decreased to $265,581 from $1,489,216, primarily due to a reduction in stock-based compensation and consulting expenses.

The company's balance sheet as of March 31, 2026, showed total assets of $248,825, down from $316,698 at the end of 2025. Current assets significantly decreased to $47,200, primarily due to a drop in cash and cash equivalents, which fell to $1,029 from $65,249. UHP's total liabilities increased to $4,441,118, compared to $4,193,149 at the end of the previous fiscal year, driven by higher accounts payable and accrued expenses.

In terms of strategic developments, UHP is actively pursuing FDA Premarket Approval (PMA) for its CelluSTAT product, which is designed to control bleeding in surgical settings. The company has faced challenges in this process, including a "Deficiencies Letter" from the FDA and a subsequent Warning Letter citing violations related to a previous clinical study. UHP has been working to address these issues and has proposed conducting additional studies to meet FDA requirements. The company is also exploring partnerships with established medical device firms to facilitate the clinical study and potential commercialization of CelluSTAT.

Operationally, UHP's focus on regulatory compliance has led to a pause in commercial activities, impacting customer engagement and product adoption rates. The company has maintained its employee headcount at 258,690, with no new stock transactions reported during the quarter. UHP's management has expressed concerns about its ability to continue as a going concern, citing negative working capital and reliance on external financing to support operations.

Looking ahead, UHP's management remains optimistic about the potential for CelluSTAT in the surgical market, contingent upon successful resolution of regulatory hurdles. The company is evaluating various financing options, including equity sales and convertible debt, to support its ongoing operations and development activities. However, the timing and success of these efforts remain uncertain, as UHP navigates the complexities of regulatory compliance and market entry.